Public market insider buying at BioSyent (V:RX)

FAX Capital Corp., a 10% Holder, acquired 25,000 Common Shares on a direct ownership basis at a price of $7.790 on June 30th, 2022. This represents a $194,750 investment into the company's shares and an account share holdings change of 1.2%.

BioSyent is in the Pharmaceuticals Sub Industry Group under the Healthcare Sector.

BioSyent Inc. (BioSyent) is a Canada-based specialty pharmaceutical company. BioSyent, through its wholly owned subsidiaries BioSyent Pharma Inc. (BioSyent Pharma) and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary of BioSyent, operates in the non-chemical insecticide business. BioSyent products include Combogesic, Aguettant System, Cathejell, Cysview, FeraMAX 150, FeraMAX Powder, Proktis-M, RepaGyn, and TIBELLA. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. Aguettant System are used for a variety of injectable medications in hospitals and the acute care setting. FeraMAX 150 is an oral hematinic indicated for the prevention and treatment of iron deficiency anemia. RepaGyn for the healing of the vaginal mucosa and the treatment of vaginal dryness.